FOSUN HEALTH Logo

Parkinson's Disease Treatment

catalogue

Parkinson's Disease Treatment

Parkinson's Disease Treatment

Treatment for Parkinson's disease does one thing: it holds function. No medication has been shown to slow the underlying process, and we do not claim one does — levodopa and everything alongside it replace a signal the brain is no longer producing, and they work for as long as they are taken. What makes treatment good or bad is not which drug is chosen but when: what the person's day needs to contain now, what the drug will cost them in five years, and at what point the conversation about a device should begin. That last one is where most people are advised too late, and it is the part of this page worth reading twice.

When treatment starts, and what it is for

Treatment begins when symptoms begin to cost something: when a person has stopped doing something because of the condition, or does it slowly enough to cost time, money or standing with others. Not on a date in the disease, and not because a scan shows something.

Saying what treatment is for matters as much as saying when it starts. It is for function and for quality of life, in the specific terms this person would define them: staying at work, driving, walking to the shop, sleeping through the night, being able to speak so that a grandchild can hear. That means the goal is set by the person and not by a motor score, and it means the plan is written against a life rather than against a stage.

Then the honest part: nothing here slows the disease down. No drug, device or supplement has been shown to alter the underlying course. What treatment does is hold function — for years longer than a person would otherwise keep it. That is a great deal, and it is not the same claim.

The drug classes, and what each one is for

Levodopa, given with a peripheral inhibitor so that it reaches the brain rather than being converted in the bloodstream, is the most effective symptomatic treatment there is. It is described in its own section below because its management is the management of the condition.

Dopamine agonists stimulate the receptor directly. They give a smoother, longer effect with less dyskinesia, so they are used to delay levodopa in younger people and to cover the night later on. Their cost is a different side-effect profile: ankle swelling, sudden daytime sleepiness, and impulse-control disorders. They are used cautiously over 70 and avoided with cognitive impairment.

MAO-B inhibitors slow the breakdown of dopamine in the brain; COMT inhibitors do the same in the periphery and are taken with each levodopa dose. Together they are how wearing-off is usually answered before anything is escalated.

Amantadine is used for dyskinesia. Anticholinergics are used occasionally for tremor and avoided in older people because of memory, bladder and eye effects. Antipsychotics for hallucinations are chosen with care, because most worsen the movement and two — clozapine and quetiapine — largely do not. Nothing here is stopped abruptly.

Levodopa: how it is taken matters as much as how much

Levodopa is absorbed in the small intestine and competes for transport with dietary amino acids. It is taken away from protein — commonly 30 minutes before a meal or an hour or more after one — and where a dose seems not to arrive at all, the question is usually when it was taken rather than how large it was.

The side effects are manageable and are worth knowing before a person stops the drug on their own: nausea early on; low blood pressure on standing, which causes more falls than the disease and is answered with water, salt where safe, compression and a review of every pressure-lowering drug; sudden daytime sleepiness, which is a reason to review driving; and hallucinations, which are the signal to reduce rather than to add.

One rule is absolute. Levodopa and the agonists must never be stopped suddenly. Abrupt withdrawal — during an illness, before an operation, because of vomiting, or because a supply ran out — can produce a syndrome of high fever, severe rigidity, confusion and autonomic instability that resembles neuroleptic malignant syndrome, can injure the kidneys, and is a medical emergency. Every person on this treatment should carry a written note of what they take, and every admission, procedure and fast should have a plan for how it is continued.

Wearing-off and dyskinesia: the order in which they are answered

When the effect of a dose stops lasting, the response is a sequence rather than a menu, and going through it out of order is how people end up on five drugs with an unchanged day.

First, establish what is actually happening with a week of notes: is the 'off' period predictable and tied to the interval, or erratic and tied to meals? Much of what looks like wearing-off is a timing problem and disappears when the doses are moved.

Then extend each dose rather than adding a drug. Shorter intervals, fractionated doses, protein moved to the evening, and a COMT or MAO-B inhibitor all make the existing levodopa last longer without adding a second set of side effects. A patch at night is next where early morning 'off' is the problem.

Then treat the dyskinesia. Peak-dose dyskinesia is handled by reducing the individual dose and shortening the interval, which flattens the peak, and by amantadine. And the honest half: a little dyskinesia is often the better trade, and the choice is the person's own after seeing both states.

Then ask whether the day is still being held. If fluctuations shape the day and the response to medication is still clear when tested, that is the point at which device treatment is assessed. Asking a year later is asking after the window has narrowed.

Deep brain stimulation: what it does, and the window it has

Deep brain stimulation delivers continuous stimulation through electrodes in the subthalamic nucleus or the globus pallidus, connected to a generator under the collarbone. It is not a lesion: it does not destroy tissue, it is adjustable, and it can be turned off. It makes the effect of medication smoother — more 'on' time without troublesome dyskinesia, and a lower total dose.

The part most people are told too late is that it has a window rather than a queue position. The best results are in people with a clear, documented response to medication whose fluctuations have become troublesome and whose cognition, balance and swallowing are still largely intact — the last three being both what the assessment depends on and what stimulation does not improve. Once dementia, frequent falls or impaired swallowing are present, it is usually not offered. The commonest reason a person is declined is that the question was asked too late.

What it does not do should be stated first: it does not cure the condition or slow it, and it does not help what never responded to medication — balance, freezing, swallowing, speech, cognition, autonomic function. Medication is not stopped afterwards; it is reduced and re-timed.

The procedure is a programme rather than an operation: evaluation first, including neuropsychology and imaging and a conversation about what will not improve; then the implant; then a period before the device is switched on; then programming over weeks to months, with medication adjusted alongside. Programming is where the benefit is made, and it is what breaks down for people who travel — an implanted device needs someone able to programme it for years, near home. That is answered before the implant rather than after.

The risks are worth hearing without euphemism: bleeding in the brain, infection, hardware problems requiring revision, and stimulation-related effects on speech, mood or cognition that are usually adjustable by changing settings. The generator is replaced after some years. MRI is possible only under specified conditions, which is why the device identification card is issued before discharge and carried thereafter.

Infusion treatment, focused ultrasound, and where they fit

Where tablets can no longer hold the day and stimulation is not chosen or suitable, continuous delivery is the alternative principle. Apomorphine by subcutaneous injection or pump is used as a rescue for sudden 'off' and as continuous treatment; levodopa-carbidopa intestinal gel through a pump into the small intestine is used where fluctuations are severe and swallowing is intact, and requires a gastrostomy and real commitment to a device and a tube.

Focused ultrasound creates a small lesion without an incision and is used mainly for tremor, usually on one side. It is an option for tremor-dominant disease in someone who is not a candidate for stimulation, and it is chosen for the tremor rather than for the condition: it does not treat bradykinesia or the other side.

Rehabilitation, speech and swallowing: the part most plans omit

Exercise is prescribed rather than recommended: aerobic work at a real intensity, resistance training, and specific practice of balance, gait and the transfers that have become difficult. It is done in the 'on' state, it is specific to what has been lost, and it is maintained for years rather than delivered as a course.

Speech and swallowing are under-treated because both are attributed to age. Therapy raises vocal loudness and articulation measurably; swallowing is assessed formally because aspiration is often silent and a chest infection is one of the commonest reasons for admission here.

The single most important thing about rehabilitation here is its duration. It is not a course that ends; it is maintained for years and rewritten as the condition changes. A plan that includes surgery but no sustained rehabilitation has spent its money on the wrong half.

Frequently Asked Questions

Will I become resistant to levodopa, and does that mean it stops working?

The drug does not stop working. What changes is the duration of its effect: the brain's capacity to store dopamine and release it smoothly is reduced, so each dose works for a shorter time and the day begins to break into 'on' and 'off'. That is a problem of timing and it is answered by timing — shorter intervals, fractionated doses, a drug that extends each dose — before it is answered by adding new drugs. Tolerance in the sense of needing ever more for the same effect is not what is happening.

Is deep brain stimulation a last resort?

No, and treating it as one is the most common way people miss it. It is assessed at a defined point: the response to medication is still clear, but wearing-off and dyskinesia have begun to shape the day, and cognition, balance and swallowing are still largely intact. Waiting until the day is dominated by 'off', falls or swallowing trouble usually means waiting until the assessment can no longer be offered. If your day is fragmenting and medication still clearly helps when it works, that is the time to ask the question.

Can I have the stimulation and then stop my medication?

Usually not entirely. Stimulation smooths the effect of medication rather than replacing it, and most people reduce their dose rather than stop it — often substantially, which is itself worthwhile because it reduces dyskinesia and the side effects of the drugs. Some medication continues. Anyone who tells you that the device lets you stop treatment entirely is describing something other than what the procedure does.

I already have an implant and I cannot get it programmed where I live. What then?

This is a real situation and it is one of the reasons we plan for follow-up explicitly rather than assuming it. Programming is where the benefit is made, and a device that cannot be adjusted is a device that is not doing its job. Bring the device identification card, the model and the last programming settings if you have them, and say what the current problems are and when they began. The first step is a records review, which does not require travel, and which states whether reprogramming, a medication adjustment alongside it, or a hardware problem is the likely explanation.

Ask whether the window is still open

If your day is fragmenting and medication still helps clearly when it works, the question of a device is a current question rather than a future one, and it is worth asking before the next year passes. Send the medication list with doses and times, a week of notes on which hours are good, any documented drug challenge, the imaging images themselves, and — if you already have an implant — the device identification card and the last programming settings. A neurologist with a movement-disorder interest will return a written opinion within about 48 hours of complete records arriving, stating whether the response to medication is established, whether the problem is timing or drug choice, and whether a device should be assessed now.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*